

September 5, 2024 04:01 AM GMT

Canada Economics and Global Macro Strategy | North America

BoC Reaction: Three in a Row

The BoC cut its policy rate by 25bps to 4.25% and made no change to its QT plan. We maintain our call for two additional cuts this year to reach 3.75% by end-2024.

Economics: As we expected, the Bank of Canada (BoC, or the Bank) moved ahead with its third 25bp cut and lowered its policy rate to 4.25%. Further progress on inflation and a desire to lift economic growth led to the September cut. The Bank reiterated that if inflation continues to ease in line with its July forecasts, "it is reasonable to expect further cuts", though it will continue to take its rate decisions "one at a time." The Bank also continued to press ahead with its current balance sheet normalization plan.

We expect [two more 25bp cuts this year](#) to reach 3.75% by end-2024 and sequential cuts until 2.50% in July 2025. We also maintain our call for QT to end in mid-2025.

Global Macro Strategy: Overall, the September meeting provided little new information to investors. However, the press conference illustrated that the Governing Council is more seriously starting to consider scenarios in which a 50bp rate cut can be appropriate at future meetings. We see room for markets to price in a lower terminal rate and continue to recommend receiving June 2025 BoC. We also continue to recommend long GBP/CAD positions.

MORGAN STANLEY & CO. LLC

Lenoy Dujon

US/Canada Economist

Lenoy.Dujon@morganstanley.com

+1 212 761-2779

Andrew M Watrous

Strategist

Andrew.Watrous@morganstanley.com

+1 212 761-5287

Zoe K Strauss

Strategist

Zoe.Strauss@morganstanley.com

+1 212 761-0407

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

Canada Economics: Hat Trick


Lenoy Dujon

The Bank cut by 25bps to lower its policy rate to 4.25%. The September cut was fueled by two reasons: 1) Inflation continues to ease in accordance with the Bank's expectations, and 2) The Bank wants to see growth pickup to absorb the excess slack in the economy.

Governor Macklem reiterated that "it is reasonable to expect further cuts in our policy rate", so long as inflation is in line with the Bank's July forecasts. However, the Bank remained tight-lipped on the path of future rate cuts as it will assess the data as it comes and "take [its] monetary policy decisions one at a time."

As the Bank continues to express confidence that inflation will return to the 2% target, we see the BoC continuing to ease monetary policy. Further, with the Bank wanting to lift economic growth to absorb the slack in the economy, we think this aligns with [our view](#) that the Bank can put through sequential 25bp cuts through 3Q25 to do so. **We expect two more 25bp cuts this year (October and December) to reach 3.75% by end-2024 and further cuts to 2.50% in July 2025 (Exhibit 1).**

Exhibit 1: We expect the policy rate to fall to 3.75% in 2024, then further to 2.50% in 3Q25



Source: Bank of Canada, Morgan Stanley Research forecasts

There was "strong consensus" for a 25bp cut at the September meeting. However, when asked about a 50bp cut, Macklem acknowledged that the Governing Council discussed different scenarios around the future rate path. If upward pressures on inflation "prove to be stronger" than the Bank expects, or if there is less slack in the economy than the Bank estimates, Macklem said it would be appropriate to "slow the pace of [rate] declines". On the other hand, if inflation is weaker than the Bank expects, it could "take a bigger step" in terms of rate cuts. Nonetheless, the incoming data remain important for the Bank's future decisions.

Macklem reaffirmed that the Bank is focused on symmetrical risks to inflation, as the Governing Council "care[s] as much about inflation being below the target as [they] do above." This comes as the Bank judged that excess supply in the economy "continues to

put downward pressure on inflation", but still sees shelter inflation and other services as "holding inflation up". As such, the Bank continues to assess the impact of these two "opposing forces" on inflation.

The Bank's view on the labor market was unchanged. With the unemployment rate having risen to 6.4% as of July, up from up from 5.7% in January and 5.4% last year, the Bank has judged that the labor market "**continues to slow**".

On monetary policy divergence with the Fed, Governor Macklem did not express concern. Macklem acknowledged that there are limits to this divergence, but they have not "become a constraint" on the Bank's monetary policy decisions. With markets now expecting the Fed to start cutting rates this year, Macklem said that divergence "doesn't look like it is getting bigger". **We expect the Fed's cutting cycle to start in September and continue with 25bp cuts through mid-2025.**

Lastly on QT, the Bank made no change to its current plan to run down its balance sheet until settlement balances reach ~C\$20-60 billion. Based on the Bank's maturity profile of its asset holdings, the Bank expects this range to be reached "sometime in 2025." **This remains in line with our expectations for its current QT plan to end in mid-2025.**

Global Macro Strategy: A 'Wake Me Up When September Ends' Moment

Zoe Strauss, Andrew Watrous

The September meeting did not provide investors with much new information. The only significant insight was an acknowledgement during the press conference that the BoC would be willing to cut its policy by more than 25bp at future meetings, if needed.

This dovish bias from the BoC is consistent with our bearish view on CAD. We continue to recommend long GBP/CAD positions and receiving June 2025 BoC.

50bp? For the first time, the BoC provided a bit more guidance on the pace of cuts.


Governor Macklem [mentioned](#) during the press conference that there was a strong consensus for a 25bp rate cut – this was in response to a question on whether in a 50bp rate cut was discussed at the September meeting.

Governor Macklem then went on to explain that the Governing Council discussed scenarios for future decisions in terms of when it could be appropriate to slow the pace of cuts, as well reduce its policy rate by more than 25bp.

We think that the explicit acknowledgement of the possibility of a more aggressive rate-cutting cycle will likely keep a risk premium in pricing of near-term BoC meetings embedded, especially since the BoC [highlighted](#) downside risks to its 2H growth forecast ([Exhibit 2](#)).


Governor Macklem stressed that the Summary of Deliberations will provide more insights into the scenarios that were discussed. The summary will be released on September 18.

Exhibit 2: The BoC has started discussing scenarios under which a more aggressive pace of rate cuts could be appropriate



Source: MS STIR Desk, Morgan Stanley Research

Exhibit 3: Shelter remains the main upward pressure to inflation



Source: MS STIR Desk, Morgan Stanley Research

Rate cut guidance: The rate cut guidance was kept unchanged in the statement. At the September meeting, the BoC continued to [indicate](#) that "...it is reasonable to expect further cuts in our policy rate".


With regards to the timing of rate cuts, the Governing Council reiterated that it would take "monetary policy decisions one at a time."

Balance of risks: The BoC [repeated](#) its balanced risk approach to inflation, which is an adjustment the BoC made in [July](#).

The final paragraph of the rate announcement repeated that "excess supply in the economy continues to put downward pressure on inflation, while price increases in shelter and some other services are holding inflation up."


The Governing Council is assessing the impact of these two "opposing forces" on inflation.

Exhibit 4: Core inflation measures continue to ease



Source: Bloomberg, Macrobond, Morgan Stanley Research

Exhibit 5: Until the summer, FX traded mostly in Regime 2 YTD, but we now see risks of entering the USD Bear Regime (Regime 1), where CAD/USD tends to strengthen



Source: Bloomberg, Macrobond, Morgan Stanley Research

Inflation progress: The BoC acknowledged the recent progress on inflation without giving any update on the outlook from here – partly because the September decision was a non-forecast meeting.

The BoC continued to emphasize that "... shelter price inflation is still too high. It remains the biggest contributor to overall inflation, despite some early signs of easing" ([Exhibit 3](#)).

At the same time, the Governing Council also [concluded](#) that "...there is little evidence of broad-based price pressures" ([Exhibit 4](#)).

Labor market: The rate announcement and opening statement put a bit less emphasis on the labor market relative to the July documents.

Markets initially therefore interpreted the rate announcement and opening statement as marginally hawkish (Canadian 2y yields reversed their initial decline slightly after the 9:45am EDT release).

However, the overall tone around the slack in the labor market remained the same, even if the BoC did not decide to spend as many words on the status of the labor market.

As mentioned above, Governor Macklem's remarks during the press conference were more explicit than at the July meeting regarding the Council's willingness to cut by 50bp if growth data disappoint. Canadian 2-year yields started to head back lower during Governor Macklem's comments.

Bottom line – the September meeting did not provide investors with materially new information. So what to watch next?

For BoC rate expectations, we are mostly focused on [labor market](#) and growth data (both domestic and in the US).

Canadian inflation data remain important, but we think these data carry a slightly lower weight for investors' expectations right now, given the BoC's confidence in bringing inflation back to target over the medium term.

For USD/CAD, we are more focused on risks around the broad USD as opposed to BoC expectations at the moment.

We recently [discussed](#) that the USD's balance of risks has shifted from bullish to bearish after FOMC Chair Powell's Jackson Hole speech. That is, risks of the USD Bear Regime (Regime 1) of our [Real Yield USD Framework](#) have increased. CAD tends to strengthen versus the USD in this regime ([Exhibit 5](#)).

We recommend long GBP/CAD positions as a way to express our expectation of BoE-BoC divergence.

- **Trade idea: Maintain receive June 2025 BoC at 2.97**
- **Trade idea: Maintain long GBP/CAD at 1.7767 with a target of 1.80 and stop of 1.70**

Fixed Income Valuation Methodology and Risks

TRADE	ENTRY LEVEL	ENTRY DATE	RATIONALE	RISKS
Receive June 2025 BoC	3.19%	9-Aug-24	We believe markets can price in a deeper BoC cutting cycle into 2025. In addition, developments in the Canadian labor market, and the BoC's increased focus on slack in the labor market, should increase the possibility that markets will price in a higher risk premium of front-loaded policy normalization.	A sharp rebound in economic activity in Canada coupled with upside surprises in CPI data.
Long GBP/CAD	1.73	21-Jun-24	We think increasing divergence between BoC and BoE pricing could increase GBP/CAD's attractiveness as a carry trade, pushing the pair higher.	BoC and BoE rates converge as the BoE cuts faster than expected or higher inflation in Canada limits BoC rate cuts.

Source: Morgan Stanley Research

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Zoe K Strauss; Andrew M Watrous.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Canada.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Canada. The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of August 31, 2024)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1418	38%	338	44%	24%	649	39%
Equal-weight/Hold	1736	47%	351	46%	20%	793	47%
Not-Rated/Hold	4	0%	0	0%	0%	1	0%
Underweight/Sell	573	15%	76	10%	13%	230	14%
Total	3,731		765			1673	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next

12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC & E*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of Canada.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser.

The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at 18th Floor, Tower 2, One World Center, Plot- 841, Jupiter Textile Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400013, India Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

The following authors are Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity securities: Zoe K Strauss; Andrew M Watrous.

The following authors are neither Equity Research Analysts/Strategists nor Fixed Income Research Analysts/Strategists and are not opining on or expressing recommendations on equity or fixed income securities: Lenoy Dujon.

© 2024 Morgan Stanley